Key result
Diabetes and hyperglycemia worsen VTE mortality despite inconclusive evidence as independent VTE risk factors.
Why the study?
Although diabetes mellitus is linked to vascular disease, demonstrating its association with venous thromboembolism has been challenging, and the mechanisms and therapeutic strategies require further examination.
Does diabetes mellitus or hyperglycemia independently increase the risk of venous thromboembolism and worsen clinical outcomes in patients who develop VTE?
Does diabetes mellitus or hyperglycemia independently increase the risk of venous thromboembolism and worsen clinical outcomes in patients who develop VTE?
Answers are grounded in this paper and cite their sources.
While in vitro evidence shows hyperglycemia promotes hypercoagulability and clinical data link it to worse VTE mortality and bleeding risk, meta-analyses adjusting for confounders like obesity have not conclusively established diabetes mellitus as an independent risk factor for developing VTE.
Patients with diabetes mellitus (DM) have chronically increased blood glucose and multiple physiologic alterations that place them at elevated risk for vascular disease. Traditionally, this vascular risk has mainly referred to chronic atherosclerosis and embolic arterial disease. Retrospective studies have suggested an increased risk of a pulmonary embolism (PE) and deep vein thrombosis (DVT), collectively termed venous thromboembolism (VTE), in patients with DM, but this association has been difficult to demonstrate with comorbidities such as obesity in meta-analysis. Clinical studies have demonstrated worse outcomes for patients with DM who suffer from VTE. In vitro studies show multiple physiologic abnormalities with chronic inflammation, endothelial dysfunction, dysfunction in the coagulation cascade, as well as other changes that drive a vicious cycle of hypercoagulability. Aggressive medical management of DM can improve vascular outcomes, and some anti-hyperglycemic therapies may modify VTE risk as well. Anticoagulation strategies are similar for patients with DM, but with some added considerations, such as high rates of comorbid renal dysfunction. More research is needed to definitively categorize DM as a risk factor for VTE and elucidate specific therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Panchagnula et al. (2024) conducted a review in Diabetes mellitus, hyperglycemia, and venous thromboembolism (deep vein thrombosis and pulmonary embolism). Hyperglycemia and diabetes mellitus vs. Normoglycemia / absence of diabetes mellitus was evaluated on Venous thromboembolism incidence and clinical outcomes (including mortality and bleeding). Hyperglycemia and diabetes mellitus drive prothrombotic states in vitro and worsen venous thromboembolism mortality clinically, though their role as independent VTE risk factors remains inconclusive.
Synapse has enriched 10 related papers. Consider them for comparative context: